Entering text into the input field will update the search result below

ImmunoGen tanks on Roche Phase 3 failure

Dec. 19, 2014 8:44 AM ETImmunoGen, Inc. (IMGN) StockRHHBY, IMGNBy: Douglas W. House, SA News Editor2 Comments
  • ImmunoGen (NASDAQ:IMGN) plummets 40% premarket on robust volume in response to Roche's (OTCQX:RHHBY) announcement that its Phase 3 trial evaluating Kadcyla (trastuzumab emtansine) failed to significantly improve progression-free survival as a first-line therapy in breast cancer patients.
  • Kadcyla was developed based on ImmunoGen's ADC technology which uses tumor-targeting antibodies to deliver an ImmonGen cell-killing agent to cancer cells.
  • Previously: Roche cancer drug fails label expansion trial (Dec. 19, 2014)

Recommended For You

Related Stocks

SymbolLast Price% Chg
IMGN--
ImmunoGen, Inc.